Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous mycobacteria

• Published in: Antimicrobial agents and chemotherapy Vol. 65; no. 5
• Main Authors: Schulthess, Bettina, Schäfle, Daniel, Kälin, Nicole, Widmer, Tamara, Sander, Peter
• Format: Journal Article
• Language: English
• Published: United States 01.05.2023
• ISSN: 1098-6596
• DOI: 10.1128/AAC.02131-20

Recent outbreaks of cardiac surgery-associated infections have highlighted the importance of species differentiation within the complex and pointed to a lack of antibiotic susceptibility data for Using the MGIT 960/EpiCenter TB eXiST platform, we have determined antibiotic susceptibility patterns of 48 clinical isolates and 139 other non-tuberculous mycobacteria including 119 members of the complex and 20 towards clofazimine and other drugs used to treat infections with slowly growing nontuberculous mycobacteria (NTM). MIC , MIC and tentative epidemiological cutoff (ECOFF) values for clofazimine were 0.5 mg/L, 1 mg/L and 2 mg/L for Comparable values were observed for other complex members, lower MIC (≤0.25 mg/L), MIC (0.5 mg/L) and ECOFF (1 mg/L) values were found for Susceptibility to clarithromycin, ethambutol, rifampin, rifabutin, amikacin, moxifloxacin and linezolid was in general similar for and other members of the complex but increased for The herein determined MIC distributions, MIC and ECOFF values of clofazimine for and other NTM provide the basis for the definition of clinical breakpoints. Further studies are needed to establish correlation of susceptibility and clinical outcome.